Literature DB >> 28583372

Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation.

Matthew Wright1, Koji Takeda1, Christine Mauro2, Douglas Jennings1, Paul Kurlansky1, Jiho Han1, Lauren Truby1, Samantha Stein1, Veli Topkara3, Arthur R Garan3, Melana Yuzefpolskaya3, Paolo Colombo3, Yoshifumi Naka1, Maryjane Farr3, Hiroo Takayama4.   

Abstract

BACKGROUND: There is growing concern regarding the association between pre-transplant amiodarone exposure and post-transplant adverse outcomes. We hypothesized that amiodarone use would be associated with the development of severe primary graft dysfunction (PGD) in a dose-dependent manner.
METHODS: This was a retrospective review of 269 adult orthotopic heart transplantation (OHT) recipients at our institution between 2010 and 2014. At the time of OHT, 100 were receiving amiodarone therapy (Group 1) and 169 were not (Group 2).
RESULTS: Pre-OHT creatinine was higher in Group 1 (1.49 ± 0.63 vs 1.27 ± 0.68 mg/dl, p = 0.011). At time of listing, Group 1 had higher frequency of status 2 (42.0% vs 29.0%), and Group 2 had higher frequency of status 1A (20.7% vs 8.0%; p = 0.009). Severe PGD (mechanical circulatory support within 24 hours post-OHT) was significantly higher in Group 1 (20.0% vs 5.3%, p < 0.001). Pre-OHT amiodarone use was an independent risk factor for severe PGD (odds ratio [OR], 6.05; 95% confidence interval [CI], 2.47-14.83; p < 0.001) and in-hospital mortality (OR, 2.88; 95% CI, 1.05-7.88; p = 0.039) in multivariable analysis. Each 100-mg increase in the day-of-OHT amiodarone dose (OR, 1.55; 95% CI, 1.26-1.90) and each 18,300-mg increase in the 6-month cumulative dose (OR, 1.67; 95% CI, 1.31-2.15) was associated with increased odds of developing severe PGD (p < 0.001 for both).
CONCLUSIONS: Amiodarone use pre-OHT is independently associated with increased incidence of severe PGD and in-hospital mortality and linearly associated with increased incidence of severe PGD in a dose-dependent manner.
Copyright © 2017 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  amiodarone; extracorporeal membrane oxygenation; heart failure; orthotopic heart transplantation; primary graft dysfunction

Mesh:

Substances:

Year:  2017        PMID: 28583372     DOI: 10.1016/j.healun.2017.05.025

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

1.  Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation.

Authors:  Lauren K Truby; Lydia Coulter Kwee; Richa Agarwal; Elizabeth Grass; Adam D DeVore; Chetan B Patel; Dongfeng Chen; Jacob N Schroder; Dawn Bowles; Carmelo A Milano; Svati H Shah; Christopher L Holley
Journal:  J Heart Lung Transplant       Date:  2021-08-11       Impact factor: 10.247

2.  Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction.

Authors:  Benjamin Hoemann; Hiroo Takayama; Douglas L Jennings; Jiho Han; Masahiko Ando; Susan Restaino; Paolo Colombo; Maryjane Farr; Yoshifumi Naka; Koji Takeda
Journal:  Clin Transplant       Date:  2020-01-29       Impact factor: 2.863

Review 3.  Primary graft dysfunction after heart transplantation: a thorn amongst the roses.

Authors:  Sanjeet Singh Avtaar Singh; Jonathan R Dalzell; Colin Berry; Nawwar Al-Attar
Journal:  Heart Fail Rev       Date:  2019-09       Impact factor: 4.214

4.  Combined amiodarone and digitalis therapy before heart transplantation is associated with increased post-transplant mortality.

Authors:  Rasmus Rivinius; Matthias Helmschrott; Ann-Kathrin Rahm; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Andreas O Doesch; Philipp Ehlermann; Hugo A Katus; Edgar Zitron
Journal:  ESC Heart Fail       Date:  2020-07-01

5.  Post-Transplant Extracorporeal Membrane Oxygenation for Severe Primary Graft Dysfunction to Support the Use of Marginal Donor Hearts.

Authors:  Yasuhiro Shudo; Aiman Alassar; Hanjay Wang; Bharathi Lingala; Hao He; Yuanjia Zhu; William Hiesinger; John W MacArthur; Jack H Boyd; Anson M Lee; Maria Currie; Y Joseph Woo
Journal:  Transpl Int       Date:  2022-03-10       Impact factor: 3.782

6.  Amiodarone Use Prior to Cardiac Transplant Impacts Early Post-Transplant Survival.

Authors:  Salman S Allana; Furqan A Rajput; Jason W Smith; Lucian Lozonschi; Jinn-Ing Liou; Maryl Johnson; Takushi Kohmoto; Ravi Dhingra
Journal:  Cardiovasc Drugs Ther       Date:  2020-10-19       Impact factor: 3.727

7.  Re-Thinking Re-Synching in Left Ventricular Assist Device Recipients.

Authors:  Justin M Vader; Daniel H Cooper; Praveen Rao
Journal:  J Am Heart Assoc       Date:  2018-06-15       Impact factor: 5.501

8.  The Interaction of Amiodarone and Continuous-flow Left Ventricular Assist Device Use in Risk of Severe Primary Graft Dysfunction Following Heart Transplantation.

Authors:  Thiru Chinnadurai; Snehal R Patel; Omar Saeed; Waqas Hanif; Mercedes Rivas-Lasarte; Muhammad Farooq; Carolyne Castillo; Maria Taveras; Daphenie Fauvel; Jooyoung J Shin; Daniel Sims; Sandhya Murthy; Sasha Vukelic; Patricia Chavez; Stephen Forest; Daniel Goldstein; Ulrich P Jorde
Journal:  Transplant Direct       Date:  2022-01-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.